COR — Cencora, Inc. stock price, charts and financials

QT52Cencora, Inc.

Cencora, Inc. (NYSE: COR) is a Healthcare company in the Medical - Distribution industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
308.37
-2.97-0.95%
CORQT52Cencora, Inc.·NYSE
308.37-0.95%
Earnings
Down 1.0% — Earnings due 2026-08-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E23.73EPS (ttm)13.12Insider Own16.19%Shs Outstand194.56MPerf Week0.47%
Market Cap60.57BForward P/E15.70EPS next Y19.83Insider Trans0.01%Shs Float184.00MPerf Month7.95%
Enterprise Value70.72BPEG0.46EPS next Q-Inst Own-Short Float3.19%Perf Quarter1.08%
Income2.55BP/S0.18EPS this Y36.37%Inst Trans-Short Ratio3.24Perf Half Y-11.58%
Sales328.64BP/B17.83EPS next Y11.48%ROA3.12%Short Interest5.87MPerf YTD-7.82%
Book/sh-P/C26.61EPS next 5Y14.94%ROE115.93%52W High373.92 -17.53%Perf Year6.70%
Cash/sh-P/FCF38.88EPS past 3/5Y-0.33% -ROIC11.89%52W Low242.49 27.17%Perf 3Y65.86%
Dividend Est.2.40 (0.78%)EV/EBITDA14.15Sales past 3/5Y10.43% 11.09%Gross Margin3.47%Volatility1.87% 2.24%Perf 5Y156.65%
Dividend TTM2.35 (0.76%)EV/Sales0.22EPS Y/Y TTM73.17%Oper. Margin1.28%ATR (14)7.36Perf 10Y262.82%
Dividend Ex-DateMay 15, 2026Quick Ratio0.59Sales Y/Y TTM11.81%Profit Margin0.78%RSI (14)59.22Recom2.30
Dividend Gr. 3/5Y6.46% 5.77%Current Ratio0.95EPS Q/Q9.38%SMA201.50%Beta0.56Target Price359.00
Payout18.01%Debt/Eq3.65Sales Q/Q3.85%SMA507.93%Rel Volume0.53Prev Close311.34
Employees51,000LT Debt/Eq5.94EarningsAug 05SMA200-4.07%Avg Volume1.76MPrice308.37
IPO DateApr 04, 1995Option/ShortYes / YesEPS/Sales Surpr.0.77% -0.15%Net Debt/EBITDA2.03Volume929,498Change-0.95%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ReiteratedBarclaysOverweight$425$350
May-11-26ReiteratedWells FargoOverweight$429$331
May-08-26ReiteratedMorgan StanleyOverweight$400$342
May-07-26ReiteratedUBSBuy$415$412
Apr-08-26ReiteratedEvercore ISI GroupOutperform$420$360
Mar-17-26ReiteratedMorgan StanleyOverweight$400$380
Feb-13-26ReiteratedBarclaysOverweight$400$425
Feb-10-26ReiteratedWells FargoOverweight$354$429
Feb-05-26ReiteratedEvercore ISI GroupOutperform$400$420
Jan-29-26UpgradeMorgan StanleyEqual WeightOverweight$330$400
Latest News
Today
Jul-31-26
Jul-29-26
Jul-27-26
Jul-25-26
Jul-24-26
Jul-23-26
Jul-22-26
Jul-17-26
Jul-16-26
Jul-15-26
Jul-15-2601:56PM
Company

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue328,681321,333293,959262,173238,587213,989189,894179,589167,940
Cost of Goods Sold Incl. D&A317,283311,191285,257254,417230,986207,720185,102175,059163,828
Gross Profit11,39610,1428,7017,7567,6016,2694,7924,5304,111
Selling, General and Administrative Excl. Other7,1956,4945,6615,3104,8493,5942,7672,6642,460
Research and Development
000000000
Other Operating Expense
000000000
Operating Income4,2023,6483,0402,4472,7522,6752,0251,8671,651
Interest Expense473420249276232183159195190
Unusual Expense
Non-Operating Income (Expense)-220-970-787-10-337-271-7,160-704-284
Net Income Before Taxes3,5072,2582,0042,1612,1832,222-5,2949671,177
Income Taxes955691485428517677-1,894113-438
Consolidated Net Income2,5481,5541,5091,7451,6991,540-3,4008551,658
Net Income From Continuing Operations2,5531,5681,5191,7331,6671,545-3,4008541,616
Net Income2,5481,5541,5091,7451,6991,540-3,4008551,658
EPS (Recurring)13.128.027.608.628.157.48-16.604.077.61
EPS (Basic, Before Extraordinaries)13.128.027.608.628.157.48-16.604.077.61
EPS (Diluted)13.047.967.538.538.047.39-16.604.047.53
EBITDA4,9953,7363,3643,4093,1132,910-4,7341,6511,867
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio23.6539.2629.8921.1016.8316.1620.3812.25
Price To Sales Ratio0.180.190.150.140.120.110.100.100.12
Gross Margin3.473.162.962.963.192.932.522.522.45
Operating Margin1.281.141.030.931.151.251.071.040.98
Net Margin0.780.480.510.670.710.72-1.790.480.99
Shares Outstanding195194199205208206205210218
Market Capitalization60,13260,63144,79136,89428,14924,60719,86917,28920,104
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$393.05$353.40$313.75$274.09$234.44 Close Price0.00M2.64M5.28M7.92M10.57MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Tyler Lauren MDirectorJun 22 '26Buy270.23550148,6274,359Jun 24
DURCAN DERMOT MARKDirectorJun 18 '26Buy274.194,0001,096,76031,767Jun 22
DURCAN DERMOT MARKDirectorMay 28 '26Buy266.264,0001,065,04027,767May 28
Campbell Elizabeth SExecutive Vice PresidentMar 11 '26Option Exercise0.0012,623036,548Mar 13
Battaglia SilvanaExecutive Vice PresidentMar 11 '26Option Exercise0.008,415027,239Mar 13
Cleary James FChief Financial OfficerMar 11 '26Option Exercise0.0012,6230165,766Mar 13
Mauch Robert P.President & CEOFeb 20 '26Option Exercise86.093,762323,87169,155Feb 24
Mauch Robert P.President & CEOFeb 20 '26Sale358.943,7621,350,33265,393Feb 24
Mauch Robert P.President & CEOFeb 18 '26Sale359.461,333479,16065,393Feb 20
Mauch Robert P.President & CEOJan 20 '26Sale354.735,0961,807,70466,726Jan 22
Mauch Robert P.President & CEOJan 20 '26Option Exercise86.093,763323,95771,822Jan 22
Battaglia SilvanaExecutive Vice PresidentDec 19 '25Sale345.001,677578,56518,796Dec 22
Campbell Elizabeth SExecutive Vice PresidentDec 19 '25Sale342.103,3511,146,37723,891Dec 22
Mauch Robert P.President & CEODec 18 '25Option Exercise86.093,763323,95773,155Dec 22
Mauch Robert P.President & CEODec 18 '25Sale343.455,0961,750,22168,059Dec 22
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.